-
1.发明公开BIOSENSOR FOR CONFORMATION AND SECONDARY STRUCTURE ANALYSIS 审中-公开生物传感器ZUR KONFORMATIONSEKUNDÄRENSTRUKTURANALYSE
公开(公告)号：EP3105589A1
公开(公告)日：2016-12-21
申请号：EP15704002.3
申请日：2015-02-12
发明人： GERWERT, Klaus , WILTFANG, Jens , OLLESCH, Julian , NABERS, Andreas , SCHARTNER, Jonas , KÖTTING, Carsten
IPC分类号： G01N33/543 , G01N33/553 , G01N21/35 , G01N21/55
CPC分类号： G01N21/3577 , G01N21/05 , G01N21/552 , G01N21/6428 , G01N21/6458 , G01N33/6896 , G01N2021/6421 , G01N2800/2821 , G01N2800/2835
摘要： Provided herein is a biosensor for conformation and secondary structure analysis, notably for the direct non-invasive qualitative secondary structure analysis of a single selected protein within a complex mixture, as e.g. a body fluid, by vibrational spectroscopic methods. For the analysis it is not required that the selected substance be isolated, concentrated, or pretreated by a special preparative procedure.
摘要翻译： 本文提供了用于构象和二级结构分析的生物传感器，特别是用于复杂混合物内单个选定蛋白质的直接非侵入性定性二级结构分析。 体液，通过振动光谱法。 对于分析，不要求所选物质通过特殊的制备方法进行分离，浓缩或预处理。
-
公开(公告)号：EP3324186A1
公开(公告)日：2018-05-23
申请号：EP16199792.9
申请日：2016-11-21
IPC分类号： G01N33/68
摘要： The invention provides a method that gives direct information about the intervention of a potential drug on the secondary structure distribution of a target biomolecule, i.e., for a disease with misfolded protein, such as neurodegenerative diseases. The secondary structural change is monitored by vibrational spectroscopy. The method can be applied for prescreening of drug candidates for targeting of specific biomolecules. The effect of the drug on the secondary structure distribution is monitored label-free in real time and provides thereby direct information about the efficacy of the potential drug.
-
-
公开(公告)号：EP3324187B1
公开(公告)日：2020-03-11
申请号：EP16199805.9
申请日：2016-11-21
IPC分类号： G01N33/68 , G01N21/552
-
公开(公告)号：EP3324187A1
公开(公告)日：2018-05-23
申请号：EP16199805.9
申请日：2016-11-21
IPC分类号： G01N33/68
摘要： The invention provides a combined immuno-infrared assay for the differential diagnosis and sub classification of Alzheimer's disease into different disease stages. The method can be applied for assured disease diagnostics and patient stratification. The assay considers the label-free detection of the change within the Amyloid-beta peptide and Tau protein secondary structure distribution in bodily fluids. This secondary structure change from native to ß-sheet enriched isoforms appears years before clinical disease manifestation. Now, the combined method utilizes this shift for diagnostics based on liquid biopsies.
-
-
-
-
搜索结果
5 条记录 (耗时 0.009 秒)
